Repeat Failure For Celgene’s Revlimid At NICE On Cost Grounds For MSD
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE won’t back Celgene’s Revlimid for myelodysplastic syndromes due to high cost and a patient access scheme that benefits too few.